Old Web
English
Sign In
Acemap
>
authorDetail
>
Farah Yakub
Farah Yakub
King's College London
Electroencephalography
Schizophrenia
Roflumilast
Medicine
Phosphodiesterase Type 4
4
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
2020
Journal of Psychopharmacology
James Gilleen
Judith Nottage
Farah Yakub
Sarah Kerins
Lorena Valdearenas
Tolga Uz
Gez Lahu
Max Tsai
Frank Ogrinc
Steve C.R. Williams
Dominic H. ffytche
Mitul A. Mehta
Sukhi Shergill
Show All
Source
Cite
Save
Citations (3)
Effectiveness of behaviour change techniques on lifestyle interventions of patients with a high risk of developing cardiovascular disease. Using a qualitative approach.
2020
Health & Social Care in The Community
Lisa Kuriakose
Paulina Kuczynska
Patrick Timpel
Farah Yakub
Adam Bayley
Iliatha Papachristou Nadal
Show All
Source
Cite
Save
Citations (0)
The effects of roflumilast, a phosphodiesterase type-4 (PDE4) inhibitor, on EEG biomarkers in schizophrenia
2019
Biological Psychiatry
James Gilleen
Judith Nottage
Farah Yakub
Sarah Kerins
Lorena Valdearenas
Tolga Uz
Gez Lahu
Max Tsai
Frank Ogrinc
Steve C.R. Williams
Dominic H. ffytche
Mitul A. Mehta
Sukhi Shergill
Show All
Source
Cite
Save
Citations (0)
The effects of roflumilast, a phosphodiesterase type-4 (PDE4) inhibitor, on EEG biomarkers in schizophrenia
2019
Journal of Psychopharmacology
James Gilleen
Judith Nottage
Farah Yakub
Sarah Kerins
Lorena Valdearenas
Tolga Uz
Gez Lahu
Max Tsai
Frank Ogrinc
Steve C.R. Williams
Dominic H. ffytche
Mitul A. Mehta
Sukhi S. Shergill
Show All
Source
Cite
Save
Citations (0)
1